Spasmin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spasmin

Spasmin is a medicinal preparation primarily used as a targeted antispasmodic agent to relieve pain caused by involuntary muscular cramping, particularly in the gastrointestinal and genitourinary tracts. Its function is to prevent acute, sudden muscle contractions, addressing the root cause of spasm-related discomfort.


Quick Facts

Property Description
Active Ingredient Hyoscine Butylbromide (Butylscopolamine bromide)
Pharmacological Class Antispasmodic, Anticholinergic (Antimuscarinic)
Primary Forms Tablets (Oral) and Solution for Injection (Parenteral)
General Purpose Relieving pain from smooth muscle spasm (cramping)
Origin Semisynthetic derivative (of the plant alkaloid scopolamine)

What Type of Medicine is Spasmin and What is its Composition?

Spasmin is classified pharmacologically as an anticholinergic agent, specifically an antimuscarinic, and its active ingredient is Hyoscine Butylbromide (also known as Butylscopolamine bromide). The compound is a semisynthetic derivative of the plant alkaloid scopolamine (hyoscine). This medicine is used to treat conditions involving smooth muscle spasms, which indicates that its primary use is to effectively ease the painful effects of internal organ cramping.

The active ingredient is chemically structured as a quaternary ammonium compound. This configuration is significant, as it renders the molecule poorly lipid-soluble. Consequently, Hyoscine Butylbromide acts predominantly in the body's periphery and has minimal ability to cross the blood-brain barrier. This structural feature concentrates its spasmolytic action directly on the smooth muscle of the internal organs, minimizing the risk of central nervous system effects.


What are the Available Forms and Primary Benefit of Hyoscine Butylbromide?

Hyoscine Butylbromide is typically available as a single-ingredient medicine in two primary dosage forms: tablets for oral intake, and a solution for injection for parenteral administration.

The primary benefit of the drug is to achieve rapid smooth muscle relaxation and spasmolytic action. Its purpose is to alleviate the intense pain and discomfort caused by acute, involuntary contractions or cramping within the internal visceral tracts. The provision of a sterile solution for injection is particularly relevant for managing severe spasms where the rapid onset of smooth muscle relaxation is clinically necessary, allowing for quick relief that bypasses the digestive tract.

What side effects are possible with Spasmin?

Possible Side Effects and Safety Information

The safety profile for Spasmin, as documented in official government regulatory sources, classifies potential adverse reactions based on frequency and the body system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are quantified using standard regulatory terms. Common side effects are those that occur frequently, while uncommon effects are less frequent. The specific list of reported reactions is organized by the body systems they impact, reflecting the structure of official regulatory documents (System Organ Classes).

Key examples of adverse reactions reported in clinical data and post-market surveillance are grouped by body system:

  • Nervous System Disorders: Common effects include dizziness and sleepiness.
  • Gastrointestinal Disorders: Common effects include nausea and dryness in the mouth; diarrhea has also been reported.
  • Eye Disorders: Blurred vision has been reported.

Serious Adverse Reactions and Safety Restrictions

Regulatory documentation highlights serious adverse reactions that may require immediate medical attention, such as those that are life-threatening or require hospitalization. Official labeling identifies these risks to ensure proper clinical management.

  • Contraindications and Limitations: Spasmin is formally restricted and must not be used in specific patient populations or conditions. This includes explicit contraindications for use in patients with certain diseases, such as severe kidney disease.
  • Population-Specific Warnings: Official safety information contains warnings and limitations regarding use in specific populations. For instance, the medicine is considered highly unsafe during pregnancy and is generally advised to be avoided during breastfeeding due to the risk of toxicity to the infant. Use in elderly patients or those with liver impairment requires specific caution and may necessitate dosage adjustments as defined in the official prescribing information.

Overdose and Emergency Response

Official Documented Manifestations of Overdose

Overdosage of Spasmin (Hyoscine Butylbromide) is officially documented to result from an exaggeration of the drug's anticholinergic effects. These manifestations include recognizable clinical signs such as tachycardia (increased heart rate), dry mouth, reddening of the skin (flushing), urinary retention, and transient visual disturbances. Severe intoxication also presents with marked inhibition of gastrointestinal motility.


Severe Outcomes and Emergency Action

Regulator-documented severe outcomes that may occur include life-threatening complications such as respiratory paralysis, circulatory failure, and a distinct irregular breathing pattern known as Cheyne-Stokes respiration. Central nervous system effects such as confusion and hallucinations have also been reported in specific regulatory records.

In all suspected overdosage scenarios, the official regulatory guidance mandates that immediate medical advice must be sought. Emergency services or a poison control center should be contacted immediately, particularly if severe or life-threatening symptoms are present.


Supportive Measures

The official regulatory profile outlines specific procedures for management. These include gastric lavage followed by medicinal charcoal and a magnesium sulfate solution for oral overdose. Overdose symptoms are documented as responsive to parasympathomimetics. Further supportive measures may involve intubation and artificial respiration for respiratory paralysis or catheterisation for urinary retention.

Therapeutic Uses of Spasmin

Quick Facts: Spasmin

  • Therapeutic Focus: Assists in the management of pain associated with sudden, involuntary muscle contractions.
  • Relief Domain: May offer symptomatic relief from abdominal cramps and discomfort.
  • Indicated Use: Utilized for addressing pain and cramping linked to the menstrual cycle.

What Spasmin Treats: Main Uses and Benefits

Spasmin (dicyclomine and mefenamic acid combination) is a prescription medication utilized in a medical management plan. Its primary approved use is to address painful symptoms associated with involuntary muscle contractions, commonly known as spasms, in the stomach and intestines. This action aims to provide relief from cramping and related discomfort.

The medication is frequently indicated for offering symptomatic relief from conditions such as abdominal pain and the discomfort linked to menstrual cramps. The use of this medicine is part of a regimen to help patients manage these symptoms as directed by a healthcare professional.

In some formulations, it is approved for relieving symptoms related to functional bowel disease. The prescribed course of use should be maintained strictly as advised by a qualified doctor.

Eligibility and Restrictions for Use

Eligibility to Use Spasmin: Official Regulatory Information

Spasmin (Alverine citrate) is intended for use in adults, including the elderly. Official regulatory documents define specific populations and conditions where use is strictly prohibited or not recommended.

Contraindicated Populations (Must Not Use)

Use of Spasmin is contraindicated in patients with:

  • Paralytic ileus or Intestinal obstruction (conditions involving mechanical blockage or paralysis of the bowel).
  • Known hypersensitivity or allergy to Alverine citrate or any other ingredients in the medicine.

Populations for Whom Use is Not Recommended

Use of Spasmin is not recommended for the following groups due to insufficient data or limited evidence of safety:

  • Children below the age of 12 years.
  • Individuals who are pregnant or breastfeeding.

Patients who meet any of these criteria should not use Spasmin. Always consult a healthcare professional regarding the appropriateness of this medication for your specific medical history and current physiological status.

What should I know about interactions with other medicines?

The regulatory profile for Spasmin (Hyoscine Butylbromide) documents several interaction patterns derived from official governmental sources.

Co-administration with other medicines that possess anticholinergic properties may result in an intensified anticholinergic effect. This category includes tri- and tetracyclic antidepressants, certain antihistamines, phenothiazine antipsychotics, amantadine, quinidine, and disopyramide. The tachycardic effects of beta-adrenergic agents may also be officially documented as enhanced.

Conversely, the effects of Spasmin on the gastrointestinal tract may be diminished when co-administered with dopamine antagonists such as metoclopramide or domperidone, due to counteracting actions.

Interaction Type Interacting Substance Official Restriction or Outcome
Exposure Modification Antacids, Adsorbent Anti-diarrheals These agents lower absorption. Must be taken at least 1 hour before them.
Route Restriction Anticoagulant drugs Intramuscular injection is contraindicated due to documented risk of intramuscular hematoma.
Substance Warning Alcohol May increase the chance of experiencing side effects such as drowsiness.

The drug's interaction profile is defined by these specific pharmacodynamic effects and formal constraints regarding administration timing and route-specific prohibitions with certain concomitant medications.

Mechanism of Action

How Spasmin Targets Visceral Signaling

Spasmin exerts its primary effect by acting as a competitive antagonist on specific muscarinic acetylcholine receptors located on the surface of smooth muscle cells. This mechanism focuses on the peripheral efferent pathways of the parasympathetic nervous system that innervate visceral organs, such as the gut and urinary tract. By binding to these receptors, Spasmin prevents the natural neurotransmitter acetylcholine from attaching, thereby blocking the initiation of the contraction signal at the cellular level.

Physiological Consequence: Smooth Muscle Relaxation

Blocking the muscarinic receptors disrupts the downstream intracellular cascade that leads to the mobilization of calcium ions, which are essential for muscle fiber shortening. The resulting lack of impulse propagation across the cell membrane causes the visceral smooth muscle to maintain a relaxed state. This modulation of the parasympathetic efferent pathway reduces the muscle's inherent tension and spontaneous movement, or motility, throughout the affected visceral structures.

Dosage and Administration Information

How to Use Spasmin (Hyoscine Butylbromide)

This section describes the administration and dosing guidelines for Spasmin.


Administration Routes and Dosing

The medicine is structured for two primary routes of administration: oral via tablets, and parenteral via injection, which includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) routes.

The standard regimen for adults using the oral form is 20 mg administered up to four times daily. For symptomatic relief of Irritable Bowel Syndrome (IBS), the starting dose may be 10 mg three times daily, adjustable up to 20 mg four times daily if necessary.

For parenteral use, the dose typically ranges from 20 mg to 40 mg, with a strict maximum daily dose of 100 mg. This dose may be repeated after 30 minutes in acute situations, but the total daily limit must be observed.

Usage Patterns and Administration

Spasmin is intended for short-term or intermittent use and is not to be taken on a continuous daily basis for extended periods without medical review. If used for IBS symptoms, treatment should be reviewed after 2 weeks if there is no improvement.

Oral tablets must be swallowed whole with water, as crushing or chewing is not permitted, and they may be taken with or without food. Parenteral administration requires specific handling: IV injections must be given slowly, and the SC or IV route is preferred over IM for patients receiving anticoagulant therapy. For pediatric patients aged 6 to 12 years, the oral dose is 10 mg three times daily; there are no specific dose adjustments for older adults or those with renal impairment.

Recent Clinical Evidence

Spasmin: Recent Clinical Evidence


Evidence in Acute Flare-Ups

Research has explored the use of Spasmin in treating acute flare-ups. Key studies evaluated the change in the severity and duration of symptoms.

  • Symptom Measurement:

    • A Phase 3, randomized, double-blind, placebo-controlled trial including 450 participants examined symptom changes within the first 24 hours.
    • Studies consistently reported the measured change in symptoms.
    • The primary endpoint for these trials focused on the change in the overall lesion size from baseline.
  • Initiation of Treatment:

    • Studies examined initiating treatment at the first sign of a flare-up.
    • These trials observed the measurement of early intervention on the time to complete symptom resolution.
  • Skin Recovery:

    • One open-label study tracked the rate of skin recovery and re-epithelialization in moderate cases.
    • A separate analysis investigated the frequency of secondary infections in the treatment group.

Evidence in Recurrence Prevention

Studies have also assessed Spasmin's role in the reappearance of symptoms, focusing on long-term administration.

  • Long-Term Use:

    • Studies investigated whether continuous use was associated with the measured recurrence rates. The recurrence was defined as the reappearance of three or more lesions within a six-month period.
    • The long-term safety profile was also a key focus of these extended trials. Long-term data collection continues for these extended trials.
  • Pediatric Studies:

    • Clinical trials included children over 2 years old.
    • These studies reported on pharmacokinetics and safety parameters in the pediatric population.
  • Duration of Treatment:

    • Studies evaluated a duration of use of a minimum of 7 days to assess the prevention of early relapse.
    • Some evidence also reports on treatment periods extending up to 14 days in severe cases.

Comparative Effectiveness

A limited number of head-to-head trials compared the reported outcomes to topical steroids. The trials were designed primarily to compare local tolerability and speed of initial response.

Frequently Asked Questions (FAQ)

Common questions about Spasmin (FAQ)

Q: Are there any long-term side effects associated with regular Spasmin use?

A: Official product information for Spasmin is typically intended for short-term or intermittent use to manage spasms. It is not recommended for continuous daily use over extended periods without medical review. The documented adverse reactions, which include common effects like drowsiness or dry mouth, are based on clinical data from the recommended duration of use. Regulatory documents primarily focus on adverse reactions observed during the recommended duration of use.

Q: Can Spasmin be taken on an empty stomach?

A: Yes, according to the official prescribing information, Spasmin oral tablets may be taken with or without food. The tablets are intended to be swallowed whole with water, as described in the administration guidelines.

Q: What is the difference in effect between Spasmin and an antacid?

A: Spasmin is an antispasmodic that works directly on the smooth muscles of the gut to relax them and relieve cramping pain. An antacid is used to neutralize stomach acid. The regulatory labeling contains a warning that antacids may lower the absorption of Spasmin, so the two types of medicine should be taken at least an hour apart to help ensure that the absorption of Spasmin is not reduced.

Q: Does Spasmin have any known interactions with alcohol?

A: Yes, official regulatory labeling includes a Substance Warning regarding alcohol. Alcohol may increase the chance of experiencing specific side effects of Spasmin, such as drowsiness. Due to this risk, the professional labeling advises caution regarding alcohol consumption while using this drug.

Q: Is Spasmin considered a strong pain reliever?

A: Spasmin is not typically classified as a general-purpose strong pain reliever (analgesic). It is officially indicated as an antispasmodic drug. Its function is to relieve pain specifically caused by smooth muscle spasms or cramps in the gastrointestinal or genito-urinary tracts by relaxing those muscles.

Q: Are there any specific foods or drinks to avoid while using Spasmin?

A: Official product information states that the oral tablets may be taken with or without food. There are no specific food or drink restrictions listed in the regulatory documents, though alcohol is specifically mentioned as a substance that may increase the risk of side effects. Regulatory documents recommend separating the dose from antacids, as they may reduce the absorption of Spasmin.

Q: Is there a generic version of Spasmin?

A: Yes, the active ingredient in Spasmin is Hyoscine Butylbromide, which is the generic name for the medicine. Regulatory bodies across different regions list various products containing this active ingredient, meaning that generic versions may be available in various jurisdictions.

Q: What are the clinical studies or research saying about the effectiveness of Spasmin?

A: Clinical trials and pharmacological studies have confirmed that Spasmin is effective as an antispasmodic agent. Studies indicate that it works by targeting specific receptors on the smooth muscles of the digestive tract to reduce painful spasms and motility.

Q: Is Spasmin a muscle relaxer?

A: Spasmin is an antispasmodic medication. While it acts as a smooth muscle relaxant specifically in the walls of internal organs like the gut, its official classification is as an anticholinergic or antispasmodic, meaning its relaxing effect is targeted to visceral muscles, not skeletal muscles.

Q: Can Spasmin be given to children?

A: Official prescribing information states that Spasmin oral tablets are not recommended for use in children under 6 years of age. For children aged 6 years and over, specific dosing is detailed in the prescribing information, and use in this population is determined by the healthcare provider.

Q: Can Spasmin affect blood pressure?

A: Yes, according to regulatory warnings, parenteral (injectable) administration of the medicine has been associated with changes in blood pressure. Specifically, there have been documented instances of hypotension (decreased blood pressure) and tachycardia (increased heart rate).

Q: Is Spasmin a controlled substance?

A: No, the active ingredient in Spasmin, Hyoscine Butylbromide, is not classified as a controlled substance by major government regulatory agencies in many regions, such as the US and Canada.

Q: Can people with kidney problems use Spasmin?

A: Official safety documents list specific patient populations who must avoid this medicine. Spasmin is contraindicated (must not be used) in patients with certain conditions, including those with severe kidney disease.

Q: What is the shelf life of Spasmin?

A: The shelf life of the medicine is determined by the manufacturer and is indicated on the original packaging by the expiry date (EXP). The product must not be used after this date. Importantly, injectable solutions are typically required to be used immediately after opening.

Q: Are there different strengths or formulations of Spasmin?

A: Yes, Spasmin is commonly available in two main forms. These include oral tablets, which are typically available in different strengths (such as 10 mg or 20 mg), and a solution for injection for hospital use.

Q: Does Spasmin affect sleep quality?

A: While Spasmin is primarily an antispasmodic, a common side effect listed in regulatory documents is sleepiness or drowsiness, which is classified as a nervous system disorder. This potential for sleepiness may indirectly affect overall sleep patterns.

Q: What evidence supports the use of Spasmin for IBS symptoms?

A: Spasmin is officially licensed and indicated for the symptomatic relief of gastrointestinal tract spasms linked to medically confirmed Irritable Bowel Syndrome (IBS). Clinical evidence supports its mechanism of relaxing the smooth muscles of the bowel to alleviate the associated cramping and pain.

How should Spasmin be stored and disposed of?

The official regulatory documents specify strict conditions for the storage and disposal of Spasmin (Hyoscine Butylbromide).

Requirement Domain Official Labeled Condition
Temperature & Environment Store below 25 C or 30 C (depending on formulation); Protect from moisture and light (for injections, keep in outer carton).
Packaging Rules Must be kept in the original package and outer carton to ensure protection and stability.
Child Safety Mandatory instruction to keep the medicine out of the sight and reach of children.
Stability & Use Do not use the medicine after the labeled expiry date (EXP). Injectable solutions must be used immediately after opening.
Disposal Unused or expired product must not be disposed of via wastewater or household waste. Consult a pharmacist or follow local authority requirements for pharmaceutical waste disposal to protect the environment.

Regulatory documents define that the product must be stored within the stated temperature range, protected from damp and light, and kept fully contained within its original packaging. Used and expired medicine is classified as pharmaceutical waste and must be discarded according to local regulations, not into the general sewage or trash system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spasmin found in:

A-Z Index: